26 completed. 26 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 26 |
| Phase 2 | 3 | Completed 3 |
Follow Peritoneal Diseases: new trials by email Literature Review of Peritoneal Diseases trials Research Report on Peritoneal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis Meropenem 1000 mg, Aztreonam 2000 mg, automated peritoneal dialysis with following long time dwell - Peritoneal Dialysis Associated Peritonitis, Peritoneal Dialysis (PD) | Phase 2 / Phase 3 | Completed | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | 12 | 2021-08-31 | 2025-08-11 |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Pembrolizumab, Placebo for pembrolizumab, Carboplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1367 | 2018-12-18 | 2026-08-19 |
| Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites Rifaximin, Placebo - Cirrhosis, Ascites | Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 160 | 2018-06-05 | 2025-04-10 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Paclitaxel, Carboplatin, Atezolizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Hoffmann-La Roche | 1301 | 2017-03-08 | 2023-02-17 |
| Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Apixaban, Dalteparin, Questionnaire Administration - Cerebral Vein Thrombosis, Deep Vein Thrombosis | Phase 3 | Completed | Academic and Community Cancer Research United | 300 | 2015-11-20 | 2020-08-04 |
| Adjuvant HIPEC in High Risk Colon Cancer Adjuvant HIPEC (open/laparoscopic), Standard adjuvant systemic chemotherapy, Diagnostic laparoscopy - Colorectal Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 204 | 2015-03-01 | 2021-09-16 |
| Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis HIPEC - Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum | Phase 3 | Completed | Charite University, Berlin, Germany | 105 | 2014-03-01 | 2021-07-29 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Trabectedin, DOXIL, Dexamethasone - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Janssen Research & Development, LLC | 581 | 2013-10-16 | 2019-04-01 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Bevacizumab, Paclitaxel, Carboplatin - Genital Diseases, Female, Ovarian Diseases | Phase 3 | Completed | AGO Study Group | 927 | 2011-11-01 | 2022-07-20 |
| Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock standard therapy, hemoperfusion - Peritonitis, Septic Shock | Phase 3 | Completed | Meditor SAS | 243 | 2010-10-01 | 2013-12-18 |
| Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients laparotomy plus HIPEC - Colorectal Cancer With a Resected Minimal Synchronous PC, Ovarian Metastases | Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 150 | 2010-06-11 | 2026-04-06 |
| Protective Effect of N-acetylcysteine Against From Ototoxicity N-acetylcysteine - Hearing Loss, Extreme | Phase 2 / Phase 3 | Completed | TC Erciyes University | 60 | 2010-06-01 | 2011-11-16 |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Placebo, Paclitaxel, BIBF 1120 - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 3 | Completed | Boehringer Ingelheim | 1366 | 2009-11-17 | 2017-12-07 |
| SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection duration of antibiotics - Peritonitis | Phase 3 | Completed | University of Virginia | 518 | 2008-09-01 | 2018-05-22 |
| Treatment Duration for Abdominal Tuberculosis RNTCP Category I treatment for 6 months, RNTCP Category I treatment for 9months - Tuberculosis | Phase 3 | Completed | All India Institute of Medical Sciences | 197 | 2008-07-01 | 2015-07-03 |
| Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis spironolactone, Placebo - End Stage Renal Disease | Phase 3 | Completed | Instituto Nacional de Cardiologia Ignacio Chavez | 20 | 2008-07-01 | 2012-10-25 |
| Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer fluorouracil, leucovorin calcium, oxaliplatin - Colorectal Cancer, Primary Peritoneal Cavity Cancer | Phase 3 | Completed | UNICANCER | 264 | 2008-02-01 | 2016-08-30 |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer phenoxodiol, carboplatin, placebo - Fallopian Tube Cancer, Peritoneal Neoplasms | Phase 3 | Completed | MEI Pharma, Inc. | 142 | 2006-10-01 | 2016-07-18 |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas MiCK Assay - Adenocarcinoma, Ovarian Neoplasms | Phase 2 / Phase 3 | Completed | Pierian Biosciences | 150 | 2006-03-01 | 2018-03-12 |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer EPO906 (Patupilone), doxorubicin - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 829 | 2005-11-01 | 2020-12-17 |
Showing 20 of 26. Sign in to see all of them.
Peritoneal Neoplasms (15) · Ovarian Neoplasms (10) · Fallopian Tube Neoplasms (9) · Peritonitis (8) · Appendicitis (2) · Bacterial Infections and Mycoses (2) · Carcinoma, Ovarian Epithelial (2) · Cholecystitis (2) · Colorectal Neoplasms (2) · Genital Neoplasms, Female (2) · Kidney Failure, Chronic (2) · Neoplasms (2) · Pancreatitis (2) · Pelvic Neoplasms (2) · Abdominal Abscess (1)
Digestive System Diseases (26) · Abdominal Neoplasms (15) · Digestive System Neoplasms (15) · Neoplasms by Site (15) · Neoplasms (14) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Urogenital Diseases (12) · Adnexal Diseases (10) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Genital Diseases (10) · Gonadal Disorders (10) · Urogenital Neoplasms (10)
Carboplatin (6) · Paclitaxel (5) · Bevacizumab (3) · Doripenem (2) · Gemcitabine (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Oxaliplatin (2) · liposomal doxorubicin (2) · Acetylcysteine (1) · Aztreonam (1) · Dalteparin (1) · Dexamethasone (1) · Diathermy (1) · Docetaxel (1) · Doxorubicin (1)
Eli Lilly and Company (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · AGO Study Group (1) · Academic and Community Cancer Research United (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · All India Institute of Medical Sciences (1) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Besancon (1) · Charite University, Berlin, Germany (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Ipsen (1) · Janssen Research & Development, LLC (1) · Karl Landsteiner Insitute for Nephrology and Haemato-Oncology (1)
United States (11) · France (10) · Australia (6) · Poland (6) · Belgium (5) · Germany (5) · Italy (5) · Spain (5) · Canada (4) · Denmark (4) · Finland (4) · Russia (4) · United Kingdom (4) · Austria (3) · China (3)
Alexandra Heurgue-Berlot, MD (1) · Alexandre Louvet, MD, PhD (1) · Beate Rau, Prof. (1) · Cary Presant, MD (1) · Christophe Bureau, MD, PhD (1) · Claire Francoz, MD (1) · Daniel P Gold, PhD (1) · Didier Payen, MD (1) · Dr Govind K Makharia, MD, DM, DNB (1)
PMID 37407274, PMID 19670912, PMID 20211892, PMID 37185961, PMID 19036670, PMID 20663130, PMID 22987083, PMID 23109694, PMID 24318743, PMID 25073872, PMID 25862039, PMID 25969531, PMID 25992746, PMID 26003804, PMID 26590673, PMID 28837207, PMID 30630885, PMID 31371228, PMID 31630479, PMID 31924332, PMID 32717180, PMID 33476595, PMID 33586138, PMID 33891472, PMID 33960681, PMID 36123540, PMID 36332161, PMID 36595569, PMID 37625235, PMID 37906724, PMID 37922442, PMID 40374989, PMID 40653111, PMID 42705254
2005 (1), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2018 (1), R01GM081510 (1)